Actinium Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Actinium Pharmaceuticals, Inc. on May 11, 2017, covering events occurring on May 5, 2017. The company is incorporated in Delaware and is designated as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual amendment and does not contain financial performance data.
Material Changes
The primary material change reported is the extension of the term of the Amended and Restated Consulting Agreement with Mr. Sandesh Seth, Executive Chairman. The agreement term was extended from August 11, 2019, to February 21, 2021. All other provisions of the original agreement remain unchanged.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, risks, contingencies, or unusual items. The document serves solely to disclose the entry into a material definitive agreement regarding executive compensation terms.
Key Facts for Investor Verification
- Confirmation of the new expiration date for the Executive Chairman's consulting agreement (February 21, 2021).
- Review of the full text of the Amendment (Exhibit 10.1) to verify that no other terms were altered.
- Assessment of the impact of the extended term on future executive compensation obligations.